Cell therapies for tendons: Old cell choice for modern innovation
Although tissue engineering and cell therapies are becoming realistic approaches for medical therapeutics, it is likely that musculoskeletal applications will be among the first to benefit on a large scale. Cell sources for tissue engineering and cell therapies for tendon pathologies are reviewed...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SMW supporting association (Trägerverein Swiss Medical Weekly SMW)
2014-07-01
|
| Series: | Swiss Medical Weekly |
| Subjects: | |
| Online Access: | https://www.smw.ch/index.php/smw/article/view/1890 |
| _version_ | 1826994779203829760 |
|---|---|
| author | Lee Laurent-Applegate Anthony Grognuz Nathalie Hirt-Burri Ilias Petrou Wassim Raffoul |
| author_facet | Lee Laurent-Applegate Anthony Grognuz Nathalie Hirt-Burri Ilias Petrou Wassim Raffoul |
| author_sort | Lee Laurent-Applegate |
| collection | DOAJ |
| description |
Although tissue engineering and cell therapies are becoming realistic approaches for medical therapeutics, it is likely that musculoskeletal applications will be among the first to benefit on a large scale. Cell sources for tissue engineering and cell therapies for tendon pathologies are reviewed with an emphasis on small defect tendon injuries as seen in the hand which could adapt well to injectable cell administration. Specifically, cell sources including tenocytes, tendon sheath fibroblasts, bone marrow or adipose-derived stem cells, amniotic cells, placenta cells and platelet-derivatives have been proposed to enhance tendon regeneration. The associated advantages and disadvantages for these different strategies will be discussed and evolving regulatory requirements for cellular therapies will also be addressed. Human progenitor tenocytes, along with their clinical cell banking potential, will be presented as an alternative cell source solution. Similar cell banking techniques have already been described with other progenitor cell types in the 1950’s for vaccine production, and these “old” cell types incite potentially interesting therapeutic options that could be improved with modern innovation for tendon regeneration and repair.
|
| first_indexed | 2024-04-11T05:41:09Z |
| format | Article |
| id | doaj.art-5c643593cfbb4f02a24e3c5be66943bd |
| institution | Directory Open Access Journal |
| issn | 1424-3997 |
| language | English |
| last_indexed | 2025-02-18T09:23:23Z |
| publishDate | 2014-07-01 |
| publisher | SMW supporting association (Trägerverein Swiss Medical Weekly SMW) |
| record_format | Article |
| series | Swiss Medical Weekly |
| spelling | doaj.art-5c643593cfbb4f02a24e3c5be66943bd2024-11-02T21:08:13ZengSMW supporting association (Trägerverein Swiss Medical Weekly SMW)Swiss Medical Weekly1424-39972014-07-01144313210.4414/smw.2014.13989Cell therapies for tendons: Old cell choice for modern innovationLee Laurent-ApplegateAnthony GrognuzNathalie Hirt-BurriIlias PetrouWassim Raffoul Although tissue engineering and cell therapies are becoming realistic approaches for medical therapeutics, it is likely that musculoskeletal applications will be among the first to benefit on a large scale. Cell sources for tissue engineering and cell therapies for tendon pathologies are reviewed with an emphasis on small defect tendon injuries as seen in the hand which could adapt well to injectable cell administration. Specifically, cell sources including tenocytes, tendon sheath fibroblasts, bone marrow or adipose-derived stem cells, amniotic cells, placenta cells and platelet-derivatives have been proposed to enhance tendon regeneration. The associated advantages and disadvantages for these different strategies will be discussed and evolving regulatory requirements for cellular therapies will also be addressed. Human progenitor tenocytes, along with their clinical cell banking potential, will be presented as an alternative cell source solution. Similar cell banking techniques have already been described with other progenitor cell types in the 1950’s for vaccine production, and these “old” cell types incite potentially interesting therapeutic options that could be improved with modern innovation for tendon regeneration and repair. https://www.smw.ch/index.php/smw/article/view/1890cell therapyprogenitortenocyteshand surgeryflexor tendonneotendon |
| spellingShingle | Lee Laurent-Applegate Anthony Grognuz Nathalie Hirt-Burri Ilias Petrou Wassim Raffoul Cell therapies for tendons: Old cell choice for modern innovation Swiss Medical Weekly cell therapy progenitor tenocytes hand surgery flexor tendon neotendon |
| title | Cell therapies for tendons: Old cell choice for modern innovation |
| title_full | Cell therapies for tendons: Old cell choice for modern innovation |
| title_fullStr | Cell therapies for tendons: Old cell choice for modern innovation |
| title_full_unstemmed | Cell therapies for tendons: Old cell choice for modern innovation |
| title_short | Cell therapies for tendons: Old cell choice for modern innovation |
| title_sort | cell therapies for tendons old cell choice for modern innovation |
| topic | cell therapy progenitor tenocytes hand surgery flexor tendon neotendon |
| url | https://www.smw.ch/index.php/smw/article/view/1890 |
| work_keys_str_mv | AT leelaurentapplegate celltherapiesfortendonsoldcellchoiceformoderninnovation AT anthonygrognuz celltherapiesfortendonsoldcellchoiceformoderninnovation AT nathaliehirtburri celltherapiesfortendonsoldcellchoiceformoderninnovation AT iliaspetrou celltherapiesfortendonsoldcellchoiceformoderninnovation AT wassimraffoul celltherapiesfortendonsoldcellchoiceformoderninnovation |